Immune Acquires Worldwide Rights and Accelerates Development for the Treatment of Psoriasis and Atopic Dermatitis NEW YORK, Jan. 4, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP), “Immune”, a clinical-stage biopharmaceutical company, announced today that following the review of new efficacy data, it has entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd…